Book Review: ‘Drugs and the FDA: Safety, Efficacy, and the Public’s Trust’ by Mikkael A. Sekeres
“Drugs and the FDA” is a must-read for anyone interested in how the FDA became the trusted regulatory agency it is today.

“Drugs and the FDA” is a must-read for anyone interested in how the FDA became the trusted regulatory agency it is today.

Statutes of limitation present a significant hurdle for plaintiffs experiencing harms from COVID-19 infection.

Once sponsors decide to capture/share expanded access-derived data above and beyond that needed, what should IRBs do?

COVID-19 vaccine manufacturers refusing to share samples may be the latest example of the tragedy of the “anticommons” in biomedical research.

Interesting empirical studies, policy analyses, and editorials on health law and policy issues from September 2022.

But in the crisis, / immunities rained down, / Tossed freely around like candy at a 4th of July parade

Inefficiencies in negotiating vaccine procurement agreements during COVID-19 could have been attenuated with greater legal preparedness.

In some cases there may be value in collecting “real world data” from Expanded Access.

Biden’s new initiative takes an expansive view of the roles of biotechnology and biomanufacturing in the United States economy.
